A specialty
vaccine company
TOTAL
revenues 2022
€361.3m
Our employees
Valneva’s success stems from the engagement and expertise of more than 700 employees, who are the Company’s single largest asset.
2022 Highlights
Although 2022 was a challenging year, Valneva achieved several key milestones, further shaping its unique value proposition.
Our strategy
Valneva aims to become a highly valued, internationally known vaccine company focused on products that can make a difference in people’s lives.
Frédéric Jacotot General Counsel and Corporate Secretary
Our Corporate Governance Approach
Our commitment to Corporate Governance underpins the trust that our investors, employees and institutions have placed in us.
Corporate Social Responsibility
Valneva has defined long-term responsible business commitments, which reflect global health needs and sit across four key focus areas.